COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,585 Articles (22,905 medRxiv, 8,680 bioRxiv)

Most recent first Previous |  Page 2409: Articles 24081-24090  | Next

The impact of the COVID-19 pandemic on rabies reemergence in Latin America: the case of Arequipa, Peru
Raynor, B., Diaz, E. W., Shinnick, J., Zegarra, E., Monroy, Y., Mena, C., Castillo-Neyra, R.
10.1101/2020.08.06.20169581 — Posted: 2020-08-11 Discussion: Offsite
Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Severe Aortic Stenosis in England
Martin, G. P., Curzen, N., Goodwin, A., Nolan, J., Balacumaraswami, L., Ludman, P., Kontopantelis, E., Wu, J., Gale, C. P., de Belder, M., Mamas, M. A.
10.1101/2020.08.05.20168922 — Posted: 2020-08-11
Time to negative PCR from symptom onset in COVID-19 patients on Hydroxychloroquine and Azithromycin - A real world experience
Saleemi, S. A., Alrajhi, A., Alhajji, M., Alfattani, A., Albaiz, F.
10.1101/2020.08.05.20151027 — Posted: 2020-08-11 Discussion: Onsite
COVID-19 and Mental Health: A Study of its Impact on Students
Moghe, K., Kotecha, D., Patil, M.
10.1101/2020.08.05.20160499 — Posted: 2020-08-11
Sofosbuvir Terminated RNA is More Resistant to SARS-CoV-2 Proofreader than RNA Terminated by Remdesivir
Jockusch, S., Tao, C., Li, X., Chien, M., Kumar, S., Morozova, I., Kalachikov, S., Russo, J. J., Ju, J.
10.1101/2020.08.07.242156 — Posted: 2020-08-10
Ebselen Reacts with SARS Coronavirus-2 Main Protease Crystals
Malla, T. N., Pandey, S., Poudyal, I., Feliz, D., Noda, M., Phillips, G., Stojkovic, E., Schmidt, M.
10.1101/2020.08.10.244525 — Posted: 2020-08-10
Bi-paratopic and multivalent human VH domains neutralize SARS-CoV-2 by targeting distinct epitopes within the ACE2 binding interface of Spike
Bracken, C. J., Lim, S. A., Solomon, P., Rettko, N. J., Nguyen, D. P., Zha, B. S., Schaefer, K., Byrnes, J. R., Zhou, J., Lui, I., Liu, J., Pance, K., QCRG Structural Biology Consortium, , Zhou, X. X., Leung, K. K., Wells, J. A.
10.1101/2020.08.08.242511 — Posted: 2020-08-10
An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation
Schoof, M., Faust, B., Saunders, R. A., Sangwan, S., Rezelj, V. V., Hoppe, N., Boone, M., Billesboelle, C., Zimanyi, M., Deshpande, I., Liang, J., Anand, A. A., Dobzinski, N., Zha, B. S., Barsi-Rhyne, B., Bleyy, V., Barile-Hill, A. W., Gupta, S., Simoneau, C. R., Leon, K., White, K. M., Nock, S., Liu, Y., Krogan, N. J., Ralston, C. Y., Swaney, D. L., Garcia-Sastre, A., Ott, M., Vignuzzi, M., Quantitative Biosciences Institute (QBI) Coronavirus Research Group Structural Biology Consortium, , Walter, P., Manglik, A.
10.1101/2020.08.08.238469 — Posted: 2020-08-10 Discussion: Onsite | Offsite
The interplay of SARS-CoV-2 evolution and constraints imposed by the structure and functionality of its proteins
Jaroszewski, L., Iyer, M., Alisoltani, A., Sedova, M., Godzik, A.
10.1101/2020.08.10.244756 — Posted: 2020-08-10 Discussion: Onsite
Nonstructural protein 1 of SARS-CoV-2 is a potent pathogenicity factor redirecting host protein synthesis machinery toward viral RNA.
Yuan, S., Peng, L., Park, J. J., Hu, Y., Devarkar, S. C., Dong, M. B., Wu, S., Chen, S., Lomakin, I., Xiong, Y.
10.1101/2020.08.09.243451 — Posted: 2020-08-10

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).